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Abstract
Transthyretin (TTR)-related familial amyloid polyneuropathy (TTR-FAP) is a life-threatening autosomal dominant,
systemic disease. First symptoms usually occur from the second to over sixth decade of life with a length-
dependent axonal neuropathy with prominent involvement of the small fibers and multi-organ systemic failure.
Early diagnosis is pivotal for effective therapeutic options, but it is hampered by the heterogeneity of the clinical
spectrum which can lead to misdiagnosis with other neurological condition/disorder such as axonal sensory-motor
neuropathy (CMT2) as described in literature.
The aim of our study was to search for TTR mutations in a large cohort of selected undiagnosed axonal sensory-
motor neuropathy patients to establish if misdiagnosis is frequent or rare in the Italian population.
No TTR pathogenic variants were found in our cohort. In conclusion, our study shows that TTR testing not should
be straightforward recommended in CMT2 patients but only when “red flags” TTR’s features are present.
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Letter to the editor
Autosomal-dominant transthyretin (TTR)-related
amyloidosis usually manifests in the second to over
sixth decade with a length-dependent axonal neuropathy
with prominent involvement of the small fibers and
multi-organ systemic failure.
In Portugal and Sweden where Transthyretin Related
Familial Amyloid Polyneuropathy (TTR-FAP) is endemic,
disease prevalence ranges from 1 in 1.000 to 1 in 10.000
people. Beyond these endemic regions, the incidence of
TTR-FAP is much lower.
More than 130 different mutations of TTR have been
identified worldwide, but the first-described Val30Met
mutation remains the most common with an early onset
phenotype, which is typical in Portuguese population [1].
The prevalence of different mutations varies according
to ethnicity and geographic region. In Italy few re-
gions (Sicily, Puglia, Lazio, Piedmont, Tuscan-Emilian
Apennines) are endemic for specific mutations.
Early diagnosis is pivotal for effective therapeutic
options, but it is hampered by the heterogeneity of the
clinical spectrum in not-Portuguese populations, in
which the divergences from the canonical phenotype are
relevant [2]. In the last years many groups described pa-
tients carrying TTR mutations and showing misleading
clinical features [3, 4] or mimicking other neurological
disorders as ALS [5, 6].
In 2011, Cappellari and colleagues reported atypical
presentation of TTR-related familial amyloid polyneur-
opathy in Italian families. In their sample a relevant
percentage of patients (76,4%; 13/17) received no
diagnosis or a wrong diagnosis at onset, including
Charcot-Marie-Tooth disease (CMT) in 2 patients.
The aim of our study was to search for TTR mutations
in a large cohort of selected undiagnosed axonal
sensory-motor neuropathy patients, classified as CMT2,
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to establish if CMT could occasionally mimic TTR-FAP.
For this purpose, 98 consecutive patients, referred from
all Italian Regions and affected with late onset axonal
CMT (≥ 30 y), were enrolled at CMT Clinics of
Ospedale Policlinico San Martino. Since we were
looking for possible atypical TTR presentation, our
selected cases had clinical features quite far from
classic TTR phenotype. In particular, the mean age of
onset was 46.4 years (SD: ±12,9 y; median 45 y) and
the mean disease duration was 8.9 years (median: 4.5;
range: some months – 53 years). Main clinical fea-
tures are summarized in Table 1.
All patients resulted negative for mutations in the
most frequently mutated CMT2 genes (MPZ, MNF2,
GDAP1, GJB1, NEFL). All patients underwent neuro-
logical and neurophysiological evaluation, had regular
annual follow up at CMT Clinics and give informed
consent to this genetic study.
No pathogenic TTR variants were found in this
cohort.
Transthyretin-related amyloidosis is a severe multi-
organ disease leading to death within 10 years after the
first symptoms occur. Since several pharmacological treat-
ments are now available [7–10], it is crucial to identify any
potential case and to implement diagnostic strategies to
reach an early diagnosis and plan a tailored therapy. In the
early stages, a possible misdiagnosis with CIDP has been
often reported and different authors recommend to
consider TTR-related amyloidosis in cases presenting as
immune-mediated neuropathies not responding to immu-
nomodulant therapies [3].
Coincident Diabetes Mellitus and Monoclonal Gam-
mopathy of Undetermined Significance, both frequent
particularly in elder population, could also mask a
TTR-related amyloidosis [11].
Charcot-Marie-Tooth disease is the most frequent
inherited neuromuscular disorder and, in spite of a huge
genetic heterogeneity, has peculiar clinical hallmarks as
distal weakness and atrophy and pes cavus. The
subgroup of patients presenting with a late onset axonal
CMT2 could share some clinical features with TTR
related amyloidosis, even if the course is often slowly
instead of rapidly progressing.
Since Cappellari and colleagues identified a TTR
mutation in two patients previously classified as CMT2
patients, we decided to screen a cohort of late onset
CMT2 patients in which mutations in major CMT2-
related genes have been excluded.
The study has some limitations. The number of CMT2
patients with a late onset, screened in this project, were
referred from many Italian Regions in which TTR
amyloidosis is not endemic and limited to 98 subjects,
thus affecting the diagnostic yield.
However, although in a small sample, misdiagnosis of
TTR-FAP in CMT2 patients seems not to be common.
In conclusion, our study shows that TTR testing not
should be recommended in CMT2 patients but only
when “red flags” TTR’s features are present, such as a
rapid progressive course, carpal tunnel syndrome
particularly in males, cardiologic involvement or signs
suggesting autonomic nervous system impairment.
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Mean age 55 yr
Mean onset 46,4 ± 12,9 yr
Median onset 45 yr
Mean disease duration 8,9 ± 10,2 yr
Median disease duration 4,5 yr
Prevalent motor neuropathy 13,20%
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